Oral vanadyl sulfate improves insulin sensitivity in NIDDM but not in obese nondiabetic subjects

Diabetes

Volumn 45, Issue 5, 1996, Pages 659-666

  Halberstam, Meyer ^a   Cohen, Neil ^a   Shlimovich, Pavel ^a   Rossetti, Luciano ^a   Shamoon, Harry ^a  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOHYDRATE; FATTY ACID; GLUCOSE; GLYCOGEN; GROWTH HORMONE; HEMOGLOBIN A1C; HYDROCORTISONE; INSULIN; LACTIC ACID; LIPID; ORAL ANTIDIABETIC AGENT; VANADYL SULFATE;

ADULT; ARTICLE; BODY MASS; CLINICAL ARTICLE; CLINICAL TRIAL; COLORIMETRY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; GLUCOSE BLOOD LEVEL; GLYCOGEN SYNTHESIS; GLYCOLYSIS; HUMAN; INSULIN INFUSION; INSULIN SENSITIVITY; LIPID OXIDATION; LIPOLYSIS; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RADIOIMMUNOASSAY; SINGLE BLIND PROCEDURE; SPECTROPHOTOMETRY;

EID: 0029985240     PISSN: 00121797     EISSN: None     Source Type: Journal    
DOI: 10.2337/diab.45.5.659     Document Type: Article

References (49)

1. Dubyak GR, Kleinzeller G: The insulin-mimetic effects of vanadate in isolated rat adipocytes. J Biol Chem 255:5306-5312, 1980
2. Schechter Y: Insulin-mimetic effects of vanadate: possible implications for future treatment of diabetes. Diabetes 39:1-5, 1900
3. 43Ca-efflux and sugar transport in adipose tissue and in skeletal muscle. Biochim Biophys Acta 646:261-267, 1981
4. Rossetti L, Laughlin MR: Correction of chronic hyperglycemia with vartadate but not with phlorizin normalizes in vitro glycogen synthase activity in diabetic skeletal muscle. J Clin Invest 84:892-899, 1989
5. Brichard SM, Okitolonda W, Henquin JC: Long term improvement of glucose homeostasis by vanadate treatment in diabetic rats. Endocrinology 123:2048-2053, 1988
6. Cohen N, Halberstam M, Shlimovich P, Chang CJ, Shamoon H, Rossetti L: Oral vanadyl sulfate improves hepatic and peripheral insulin sensitivity in patients with non-insulin-dependent diabetes mellitus. J Clin Invest 95:2501-2509, 1995
7. Cordera R, Andraghetti G, DeFronzo RA, Rossetti L: Effect of in vivo vanadate treatment on insulin receptor tyrosine kinase activity in partially pancreatectomized diabetic rats. Endocrinology 126:2177-2183, 1990
8. Swarup G, Cohen S, Garbers DL: Inhibition of membrane phosphotyrosyl-protein phosphatase activity by vanadate. Biochem Biophys Res Comm 107:1104-1109, 1982
9. Posner BI, Faure R, Burgess JW, Bevan AP, Lachance D, Zhang-Sun G, Fantus G, Ng JB, Hall DA, Lum BS, Shaver A. Peroxovanadium compounds: a new class of potent phosphotyrosine phosphatase inhibitors which are insulin mimetics. J Biol Chem 269:4596-4604, 1994
10. Brichard SM, Desbuquois B, Girard J: Vanadate treatment of diabetic rats reverses the impaired expression of genes involved in hepatic glucose metabolism: effects on glycolytic and gluconeogenic enzymes, and on glucose transporter GLUT. Mol Cell Endocrinol 91:91-37, 1993
11. Goldfine AB, Simonson DC, Folli F, Patti ME, Kahn CR: Metabolic effects of sodium metavanadate in humans with insulin-dependent and noninsulin-dependent diabetes mellitus in vivo and in vitro studies J Clin Endocrinol Metab 80 3312-3320, 1995
12. Roden M, Liener K, Furnsinn C, Prskavec M, Nowotny P, Steffan I, Vierhapper H, Waldbausl W: Non-insulin-like action of sodium orthovanadate in the isolated perfused liver of fed, non-diabetic rats Diabetologia 36 602-607, 1993
13. Hudson TGF: Vanadium toxicology and biological significance. In Elsevier Monographs on Toxic Agents. Browing E, Ed. New York, Elsevier, 1994
14. Dai S, McNeil JH: One-year treatment of non-diabetic and streptozotocin-diabetic rats with vanaclyl sulphate did not alter blood pressure or haematological indices. Pharmacol & Toxicol 74:110-115, 1994
15. Finegood DT, Bergman RN, Vranic M: Estimation of endogenous glucose production during hyperinsulinemic-euglycemic glucose clamp comparison of unlabeled and labeled glucose infusates. Diabetes 36:914-924, 1987
16. Hawk P. The Kjeidahl Method. In Practical Physiological Chemistry. 12th ed. Toronto, Blakiston, 1947, p. 814-822
17. Kushner RF: Bioelectrical impedance analysis: a review of priciples and applications. J Am Coll of Nutr 11:199-209, 1992
18. Wolfe RR: Total body water. In Tracers in Metabolic Research. New York, Alan R. Lise, 1984, p. 175-178
19. Young AA, Bogardus C, Wolfe-Lopez D, Mott DM: Muscle glycogen synthesis disposition of infused glucose in humans with reduced rates of insulin-mediated carbohydrate storage. Diabetes 37:303-308, 1988
20. Rossetti L, Giaccari A: Relative contribution of glycogen synthesis and glycolysis to insulin-mediated glucose uptake: a dose-response euglycemic clamp study in normal and diabetic rats. J Clin Invest 85:1785-1792, 1990
21. Rossetti L, Lee YT, Ruiz J, Aldridge S, Shamoon H, Boden G. Quantitation of glycolysis and skeletal muscle glycogen synthesis in humans. J Physiol 265:E761-E769, 1993
22. Sotsky MJ, Shilo S, Shamoon H: Regulation of counterregulatory hormone secretion in man during exercise and hypoglycemia. J Clin Endocrinol Metab 68:9-17, 1989
23. Novak M. Colorimetric ultramicro method for determination of free fatty acids J Lipid Res 6:431-433, 1965
24. Gawehn K: D-lactate. In Methods of Enzymatic Analysis. Vol. 6, Bergmeyer H, Gassl M, Eds. New York, VCH, 1986, p. 583-592
25. Steele R: Influences of glucose loading and of injected insulin on hepatic glucose output. Ann NY Acad Sci 82:420-430, 1959
26. Lusk G: Animal calorimetry: analysis of the oxidation of mixtures of carbohydrate and fat. J Biol Chem 59:41-42, 1924
27. World Health Organization: Vanadium in Environmental Health Criteria 81. Finland, World Health Organization, 1988
28. +) ATPase inhibitor found in ATP derived from muscle J Biol Chem 252:7421-7423, 1977
29. Lyonnet B, Martz F, Martin E: L'emploi thérapeutique des derives du vanadium. La Presse Medicale 1:191-192, 1899
30. Heyliger CE, Tahilani AG, McNeill JH: Effect of vanadate on elevated blood glucose and depressed cardiac performance of diabetic rats. Science 227:1474-1477, 1985
31. D'Onofrio F, Le MQ, Chiasson JL, Srivastava AK: Activation of mitogen-activating (MAP) kinases by vanadate is independent of insulin receptor autophosphorylation. FEBS Lett 340 269-275, 1994
32. Carey JO, Azevedo JL, Morris PG, Pories WJ, Dohm GL: Okadaic acid, vanadato, and phenylarsine oxide stimulate 2-deoxyglucose transport in insulin-resistant human skeletal muscle. Diabetes 44:682-688, 1995
33. Pugazhenthi S, Khandelwla RL: Insulin-like effects of vanadate on hepatic glycogen metabolism in nondiabetic and streptozotocin-induced diabetic rats. Diabetes 39-821-827, 1990
34. Yki-Jarvinen H: Glucose toxicity. Endocr Rev 13:415-431, 1992
35. Rossetti L, Smith D, Shulman GI, Papachristou D, DeFronzo RA. Correction of hyperglycemia with phlorizin normalizes tissue sensitivity to insulin in diabetic rats. J Clin Invest 79:1510-1515, 1987
36. Brichard SM, Henquin JC, Girard J: Phlorizin treatment of diabetic rats partially reverses the abnormal expression of genes involved in hepatic glucose metabolism Diabetologia 36:292-298, 1993
37. Chaliss RAJ, Leighton B, Lozeman FJ, Budohoski L, Newsholme EA: Effects of chronic administration of vanadate to the rat on the sensitivity of glycolysis and glycogen synthesis in skeletal muscle to insulin. Biochem Pharmacol 36:357-361, 1987
38. Brichard SM, Ongemba LN, Henquin JC. Oral vanadate decreases insulin muscle resistance in obese fa/fa rats. Diabetologia 35:522-527, 1992
39. De Tata V, Novelli M, Cavallini G, Masiello P, Gori Z, Bergamini E: Beneficial effects of the oral administration of vanadyl sulphate on glucose metabolism in senescent rats. J Gerontol 48:B191-B195, 1993
40. Leighton B, Cooper GJS, DeCosta C, Foot EA: Peroxovanadates have full insulin-like effects on glycogen synthesis in normal and insulin-resistant skeletal muscle. Biochem J 276:289-292, 1991
41. Brichard SM, Ongemba LN, Girard J. Henquin JC: Tissue-specific correction of lipogenic enzyme expression in diabetic rats given vanadate Diabetologia 37:1065-1072, 1994
42. Sekar N, Govindasamy S: Effects of vanadate on plasma lipoprotein profiles in experimental diabetic rats. Biochem Int 23:935-940, 1991
43. Malabu UH, Dryden S, McCarthy HD, Kilpatrick A, Williams G: Effects of chronic vanadate administration in the STZ-induced diabetic rat: the antihyperglycemic action of vanadate is attributable entirely to its suppression of feeding. Diabetes 439-15, 1994.
44. Dai S, Thompson H, McNeill JH: One-year treatment of streptozotocin-induced diabetic rats with vanadyl sulphate Pharmacol & Toxicol 74:101-109, 1994
45. Zaporowska H, Wasilewski W: Haematological effects of vanadium on living organisms. Comp Biochem Physiol 102C:223-231, 1992
46. Dafnis E, Spohn M, Lonis B, Kurtzman NA, Sabatini S. Vanadate causes hypokalemic distal renal tubular acidosis. Am J Physiol 262.F449-F453, 1992
47. Wenzel UO, Foucjueray B, Biswas P, Grandaliano G, Choudhury GG, Abboud HE: Activation of mesangial cells by the phosphatase inhibitor vanadate: potential implications for diabetic nephropathy. J Clin Invest 95:1244-1252, 1995
48. Boscolo P, Carmignani M, Volpe AR, Felaco M, Del Rosso G, Porcelli G, Giuliano G: Renal toxicity and arterial hypertension in rats chronically exposed to vanadate. Occup & Environment Med 51:500-503, 1994
49. Cam MC, Pederson RA, Brownsey RW, McNeill JH: Long-term effectiveness of oral vanadyl sulfate in streptozotocin-diabetic rats. Diabetologia 36:218-224, 1993